A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis

Michael Y. Wang, Jonathan K. Armstrong, Timothy C. Fisher, Herbert J. Meiselman, Gordon J. McComb, Michael L. Levy

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE: Intraoperative bone hemostasis can be accomplished using surgical beeswax (bone wax). However, bone wax locally interferes with osteogenesis, and its use is avoided when bone fusion is critical. We describe the use of a Pluronic copolymer blend as a biocompatible, absorbable, hemostatic agent. METHODS: A rat femur defect model and a femur gap nonunion model were used. For each surgical model, 24 rats were divided into three treatment groups, i.e., those receiving bone wax implants, Pluronic (90% Pluronic P85/10% Pluronic F88) implants, or no implants (control group). After 10, 21, or 42 days, animals were killed and femora were removed for radiographic analysis and hematoxylin and eosin staining. RESULTS: In the femur defect model, no differences were observed between the Pluronic-treated and control groups; hematoxylin and eosin staining demonstrated bone formation and osteocytes within the defect. In the femur gap nonunion model, no fusions occurred in any group. Development of an osseous callus at the gap site was observed for the control and Pluronic-treated groups. In both models, rats that received bone wax implants exhibited no osseous growth. CONCLUSION: The Pluronic blend exhibits handling properties similar to those of bone wax, readily achieves hemostasis, and does not inhibit bone regrowth. Pluronic compounds may serve as effective absorbable hemostatic agents for the treatment of bone bleeding in sites where fusion is critical. In addition, this copolymer blend may find use as a vehicle for the short-term release of pharmacological agents, which may further reduce the incidence of infections, reduce inflammation, and improve fusion rates.

Original languageEnglish
Pages (from-to)962-968
Number of pages7
JournalNeurosurgery
Volume49
Issue number4
StatePublished - Oct 16 2001
Externally publishedYes

Fingerprint

Poloxamer
Hemostatics
Osteogenesis
Bone and Bones
Femur
Hematoxylin
Eosine Yellowish-(YS)
Hemostasis
Staining and Labeling
Anatomic Models
Osteocytes
Control Groups
Bony Callus
bone wax
Pharmacology
Hemorrhage
Inflammation
Incidence
Growth

Keywords

  • Bone hemostasis
  • Bone wax
  • Osteogenesis
  • Pluronic

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Wang, M. Y., Armstrong, J. K., Fisher, T. C., Meiselman, H. J., McComb, G. J., & Levy, M. L. (2001). A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis. Neurosurgery, 49(4), 962-968.

A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis. / Wang, Michael Y.; Armstrong, Jonathan K.; Fisher, Timothy C.; Meiselman, Herbert J.; McComb, Gordon J.; Levy, Michael L.

In: Neurosurgery, Vol. 49, No. 4, 16.10.2001, p. 962-968.

Research output: Contribution to journalArticle

Wang, MY, Armstrong, JK, Fisher, TC, Meiselman, HJ, McComb, GJ & Levy, ML 2001, 'A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis', Neurosurgery, vol. 49, no. 4, pp. 962-968.
Wang MY, Armstrong JK, Fisher TC, Meiselman HJ, McComb GJ, Levy ML. A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis. Neurosurgery. 2001 Oct 16;49(4):962-968.
Wang, Michael Y. ; Armstrong, Jonathan K. ; Fisher, Timothy C. ; Meiselman, Herbert J. ; McComb, Gordon J. ; Levy, Michael L. / A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis. In: Neurosurgery. 2001 ; Vol. 49, No. 4. pp. 962-968.
@article{af433b333370447e9cdf8481dbd39110,
title = "A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis",
abstract = "OBJECTIVE: Intraoperative bone hemostasis can be accomplished using surgical beeswax (bone wax). However, bone wax locally interferes with osteogenesis, and its use is avoided when bone fusion is critical. We describe the use of a Pluronic copolymer blend as a biocompatible, absorbable, hemostatic agent. METHODS: A rat femur defect model and a femur gap nonunion model were used. For each surgical model, 24 rats were divided into three treatment groups, i.e., those receiving bone wax implants, Pluronic (90{\%} Pluronic P85/10{\%} Pluronic F88) implants, or no implants (control group). After 10, 21, or 42 days, animals were killed and femora were removed for radiographic analysis and hematoxylin and eosin staining. RESULTS: In the femur defect model, no differences were observed between the Pluronic-treated and control groups; hematoxylin and eosin staining demonstrated bone formation and osteocytes within the defect. In the femur gap nonunion model, no fusions occurred in any group. Development of an osseous callus at the gap site was observed for the control and Pluronic-treated groups. In both models, rats that received bone wax implants exhibited no osseous growth. CONCLUSION: The Pluronic blend exhibits handling properties similar to those of bone wax, readily achieves hemostasis, and does not inhibit bone regrowth. Pluronic compounds may serve as effective absorbable hemostatic agents for the treatment of bone bleeding in sites where fusion is critical. In addition, this copolymer blend may find use as a vehicle for the short-term release of pharmacological agents, which may further reduce the incidence of infections, reduce inflammation, and improve fusion rates.",
keywords = "Bone hemostasis, Bone wax, Osteogenesis, Pluronic",
author = "Wang, {Michael Y.} and Armstrong, {Jonathan K.} and Fisher, {Timothy C.} and Meiselman, {Herbert J.} and McComb, {Gordon J.} and Levy, {Michael L.}",
year = "2001",
month = "10",
day = "16",
language = "English",
volume = "49",
pages = "962--968",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A new, pluronic-based, bone hemostatic agent that does not impair osteogenesis

AU - Wang, Michael Y.

AU - Armstrong, Jonathan K.

AU - Fisher, Timothy C.

AU - Meiselman, Herbert J.

AU - McComb, Gordon J.

AU - Levy, Michael L.

PY - 2001/10/16

Y1 - 2001/10/16

N2 - OBJECTIVE: Intraoperative bone hemostasis can be accomplished using surgical beeswax (bone wax). However, bone wax locally interferes with osteogenesis, and its use is avoided when bone fusion is critical. We describe the use of a Pluronic copolymer blend as a biocompatible, absorbable, hemostatic agent. METHODS: A rat femur defect model and a femur gap nonunion model were used. For each surgical model, 24 rats were divided into three treatment groups, i.e., those receiving bone wax implants, Pluronic (90% Pluronic P85/10% Pluronic F88) implants, or no implants (control group). After 10, 21, or 42 days, animals were killed and femora were removed for radiographic analysis and hematoxylin and eosin staining. RESULTS: In the femur defect model, no differences were observed between the Pluronic-treated and control groups; hematoxylin and eosin staining demonstrated bone formation and osteocytes within the defect. In the femur gap nonunion model, no fusions occurred in any group. Development of an osseous callus at the gap site was observed for the control and Pluronic-treated groups. In both models, rats that received bone wax implants exhibited no osseous growth. CONCLUSION: The Pluronic blend exhibits handling properties similar to those of bone wax, readily achieves hemostasis, and does not inhibit bone regrowth. Pluronic compounds may serve as effective absorbable hemostatic agents for the treatment of bone bleeding in sites where fusion is critical. In addition, this copolymer blend may find use as a vehicle for the short-term release of pharmacological agents, which may further reduce the incidence of infections, reduce inflammation, and improve fusion rates.

AB - OBJECTIVE: Intraoperative bone hemostasis can be accomplished using surgical beeswax (bone wax). However, bone wax locally interferes with osteogenesis, and its use is avoided when bone fusion is critical. We describe the use of a Pluronic copolymer blend as a biocompatible, absorbable, hemostatic agent. METHODS: A rat femur defect model and a femur gap nonunion model were used. For each surgical model, 24 rats were divided into three treatment groups, i.e., those receiving bone wax implants, Pluronic (90% Pluronic P85/10% Pluronic F88) implants, or no implants (control group). After 10, 21, or 42 days, animals were killed and femora were removed for radiographic analysis and hematoxylin and eosin staining. RESULTS: In the femur defect model, no differences were observed between the Pluronic-treated and control groups; hematoxylin and eosin staining demonstrated bone formation and osteocytes within the defect. In the femur gap nonunion model, no fusions occurred in any group. Development of an osseous callus at the gap site was observed for the control and Pluronic-treated groups. In both models, rats that received bone wax implants exhibited no osseous growth. CONCLUSION: The Pluronic blend exhibits handling properties similar to those of bone wax, readily achieves hemostasis, and does not inhibit bone regrowth. Pluronic compounds may serve as effective absorbable hemostatic agents for the treatment of bone bleeding in sites where fusion is critical. In addition, this copolymer blend may find use as a vehicle for the short-term release of pharmacological agents, which may further reduce the incidence of infections, reduce inflammation, and improve fusion rates.

KW - Bone hemostasis

KW - Bone wax

KW - Osteogenesis

KW - Pluronic

UR - http://www.scopus.com/inward/record.url?scp=0034812909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034812909&partnerID=8YFLogxK

M3 - Article

C2 - 11564259

AN - SCOPUS:0034812909

VL - 49

SP - 962

EP - 968

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -